Solvemed
9 known investors
Find your way into Solvemed
862 people in our graph share verified history with the Solvemed team — schools, employers, funds. One of them is your warm intro.
Solvemed develops a smartphone-based FDA-cleared medical device for pupil size and reactivity testing in neurological exams, eliminating the need for separate hardware. The device integrates with hospital EMR systems and functions accurately in varying ambient light conditions.
Also known as Solvemed Group · Solvemed Inc.
Founders & leadership
Investors · 9
Also in the syndicate · 2
Company profile
researched Aug 2026Solvemed develops PuRe™ Pupillometer, a smartphone-based medical device application that performs pupil size and reactivity testing without dedicated hardware or disposables. The product is positioned as an alternative to two legacy approaches used in neurological examination: the medical penlight, which the company describes as subjective and variable between practitioners with no data recording or EMR integration, and conventional infrared pupillometers, which the company describes as objective but expensive, cumbersome, dependent on disposables and susceptible to ambient light effects. The app is registered as an FDA Class I medical device in the Software as a Medical Device (SaMD) product category and runs on Apple iOS, using platform security features such as Face ID.
The core technical claim is lighting invariance: Solvemed's computational pupillometry uses exposure level and initial pupil size to compute lighting-corrected parameters, which are combined to discriminate reactive from unreactive pupils, producing the Pupil Reactivity (PuRe) score. The company publishes the formulae behind the score openly for clinical researchers. Alongside the app, Solvemed offers Solvemed Connect for integration with hospital electronic medical record systems, stated to be deliverable within 12 weeks, and a secure cloud layer described as SOC2- and HIPAA-compliant with data encrypted in transit and at rest.
The company also conducts clinical and AI research. Through the EyeWarn project, a £1.2 million collaboration with University of Essex researchers led by Dr. Javier Andreu-Perez, Solvemed was granted access to the Isambard-AI supercomputer in the UK to study pupillary biomarkers and their physiological correlates; the company notes that its device produces research-grade data as a byproduct of routine clinical use rather than through separate research protocols.
Business model
Solvemed sells a software-based medical device (a smartphone app) to hospitals and clinicians, with optional paid-style EMR integration via Solvemed Connect and a supporting secure cloud service. The product is explicitly positioned as avoiding upfront capital hardware spend and recurring disposables costs associated with conventional pupillometers.
Traction
The company reports 36 employees, including 9 MBAs, 6 MDs and 4 PhDs. Clinicians in critical care settings describe routine use of the PuRe Pupillometer, and the company reports clinical research collaborations, including the £1.2 million EyeWarn project with the University of Essex supported by access to the Isambard-AI supercomputer. Company material reports assessment time reduced from 100 to 21 seconds with EMR-integrated documentation.
Latest developments
In December 2025, Solvemed Group announced it had been granted access to Isambard-AI, a $300 million UK national AI supercomputer ranked 11th on the TOP500 list and powered by more than 5,400 NVIDIA Grace Hopper Superchips, to advance research into pupillary biomarkers through the EyeWarn project with the University of Essex.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Operates in objective pupillometry for neurological assessment, competing against subjective penlight examination and conventional infrared pupillometer hardware.
Solvemed positions the PuRe score as the only pupil reactivity score unaffected by ambient light, and the product as requiring no additional hardware or plastic disposables while integrating directly with hospital EMR systems, removing manual transcription of results. The scoring methodology is released open source.
Technology
Computational pupillometry running on an iOS smartphone camera. Exposure level and initial pupil size are used to derive lighting-corrected pupillometry parameters, combined into the PuRe score to discriminate reactive from unreactive pupils; the scoring formulae are published openly. The system is an FDA Class I regulated medical device in the SaMD category, integrates with major hospital EMRs using industry-standard cryptographic protocols, leverages iOS security features including Face ID and HIPAA-compliant web services, and runs on a SOC2- and HIPAA-compliant cloud with encryption in transit and at rest. The company additionally uses large-scale AI compute, having secured access to the Isambard-AI supercomputer for pupillary biomarker research.
Go-to-market
Direct engagement with hospital clinical teams via product demonstrations requested through the company website, supported by clinician testimonials from neuro-intensivists, intensivists and anesthesiologists, clinical research collaborations, and optional EMR integration projects delivered within 12 weeks.
Hospital critical care and acute settings, including neuro-, medical-, cardiac- and surgical ICUs, trauma centers, stroke units and emergency rooms, as well as nursing staff, physicians and clinical researchers requiring pupil testing.
Geography
Activity referenced in the United States (FDA regulatory status, Solvemed Inc.) and the United Kingdom (Isambard-AI access, University of Essex collaboration, clinician at Oxford Major Trauma Centre).
History
Solvemed was co-founded by Hugo Chrost (Chief Executive Officer) and Dr Michal Wlodarski (Chief Operating Officer). Its board includes Marcin Zukowski, Wojtek Walniczek of OTB Ventures, Dr Marcus Erken and Dominik Andrzejczuk. A reported $3.5m round in September 2022 included Atmos Ventures, APEX Ventures, Tensor Ventures, Preface Ventures and Techni Ventures.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsSolvemed Group announced access to the UK's Isambard-AI system, ranked 11th on the TOP500 list and built on over 5,400 NVIDIA Grace Hopper Superchips, to support the EyeWarn project, a £1.2 million collaboration with University of Essex researchers led by Dr. Javier Andreu-Perez studying pupillary biomarkers and their physiological correlates.
Reported round of $3.5m, bringing total investment received to $4.27m.
$3.5M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 6
primary sources listed
- Solvemedsolvemed.ai · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Solvemed do?
- Solvemed makes PuRe Pupillometer, a smartphone-based FDA-regulated app for objective pupil size and reactivity testing.
- Who founded Solvemed?
- Solvemed was founded by Michal Wlodarski, PhD, Hugo Chrost.
- Who are Solvemed's investors?
- Solvemed's investors include Cambridge Angels group, Ff Venture Capital, APEX Ventures, Preface Ventures, Sunfish Partners, TechniVentures, Tensor Ventures.